

<b>PRE-APPEAL BRIEF REQUEST FOR REVIEW</b>		Docket Number (Optional) 129843.1080																	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)]  on _____  Signature _____  Typed or printed name _____	Application Number  10/753,089		Filed  01/07/2004																
	First Named Inventor  LUO, Caidian																		
	Art Unit  1793		Examiner  MARCANTONI, Paul																
<p>Applicant requests review of the final rejection in the above-identified application. No amendments are being filed with this request.</p> <p>This request is being filed with a notice of appeal.</p> <p>The review is requested for the reason(s) stated on the attached sheet(s). Note: No more than five (5) pages may be provided.</p> <p>I am the</p> <table style="width: 100%; border: none;"><tr><td style="width: 50%; vertical-align: top;"><input type="checkbox"/> applicant/inventor.</td><td style="width: 50%; vertical-align: top;">/Scott C. Sample/</td></tr><tr><td style="vertical-align: top;"><input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)</td><td style="vertical-align: top;">Signature</td></tr><tr><td style="vertical-align: top;"><input checked="" type="checkbox"/> attorney or agent of record. Registration number <u>52,189</u></td><td style="vertical-align: top;">Scott C. Sample</td></tr><tr><td style="vertical-align: top;"><input type="checkbox"/> attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____</td><td style="vertical-align: top;">Typed or printed name</td></tr><tr><td></td><td style="vertical-align: top;">(214) 999-4712</td></tr><tr><td></td><td style="vertical-align: top;">Telephone number</td></tr><tr><td></td><td style="vertical-align: top;">10/5/2010</td></tr><tr><td></td><td style="vertical-align: top;">Date</td></tr></table> <p>NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.</p>				<input type="checkbox"/> applicant/inventor.	/Scott C. Sample/	<input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)	Signature	<input checked="" type="checkbox"/> attorney or agent of record. Registration number <u>52,189</u>	Scott C. Sample	<input type="checkbox"/> attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____	Typed or printed name		(214) 999-4712		Telephone number		10/5/2010		Date
<input type="checkbox"/> applicant/inventor.	/Scott C. Sample/																		
<input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)	Signature																		
<input checked="" type="checkbox"/> attorney or agent of record. Registration number <u>52,189</u>	Scott C. Sample																		
<input type="checkbox"/> attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____	Typed or printed name																		
	(214) 999-4712																		
	Telephone number																		
	10/5/2010																		
	Date																		
<input type="checkbox"/> *Total of _____ forms are submitted.																			

This collection of information is required by 35 U.S.C. 132. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

## Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appln. No.: 10/753,089  
Applicant: LUO, et al.  
Filed: January 7, 2004  
Art Unit: 1793  
Confirmation No.: 5413  
Examiner: MARCANTONI, Paul D.  
For: FIBER CEMENT COMPOSITE MATERIALS USING  
BLEACHED CELLULOSE FIBERS

---

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRE-APPEAL BRIEF REQUEST FOR REVIEW**

In the final Office Action dated April 6, 2010, claims 1, 4-9, 11, 28 and 30-34 were rejected under 35 U.S.C. § 102(a) and (e) as being anticipated by U.S. Patent Nos. 6,506,248 and 6,346,146 ("the Duselis patents"). Furthermore, claims 1, 4-9, 11, 28, and 30-34 were rejected under 35 U.S.C. § 103(a) as being unpatentable over the Duselis patents each alone, or in view of Cook et al. (U.S. Patent No. 6,942,726) and Gregerson et al. (EP 263723). (It is noted that the Duselis patents have been, and remain, owned by the Applicant, and the obviousness-type double patenting rejections have been previously overcome via the submission of terminal disclaimers.)

Claims 1, 28 and 30 are independent. Claim 1 recites "a composite material comprising a cementitious matrix and cellulose fibers incorporated into the cementitious matrix, wherein the cellulose fibers comprise a blend of bleached and unbleached cellulose fibers and wherein the bleached cellulose fibers comprise between about 10 and 17 weight percent of the total cellulose fibers incorporated into the matrix." (some punctuation omitted for clarity)

**35 U.S.C. § 102(a)/(e) REJECTION**

Reconsideration of the rejection under 35 U.S.C. § 102 is requested because the broad genus disclosed in the *Duselis* patents does not anticipate the claimed range. The two sentences shared by both patents and cited in support the rejection are: "The cellulose fibres may be bleached, unbleached, partially bleached or mixtures thereof. The fibrous materials may be present in a concentration of 0 to 25 wt %, preferably 2 to 16 wt %, more preferably 5 to 15 wt % based on the weight of the dry formulation." Notice that the percentages are per weight of the *dry formulation*. In contrast, the pending application discloses and claims a percentage of bleached fibers per total *cellulose fibers*, namely, 10 to 17 weight percent per total cellulose fibers, and that the cellulose fibers in total comprise about 0.5% to 20% of the dry formulation. Thus, the amount of *bleached* fibers recited in the pending claims comprise between about 0.06% to about 3.4% in terms of dry formulation. It is understood that it is this range the examiner refers to as overlapping the *Duselis* patents' range of 0 to 25 weight percent *total cellulose fibers* per dry formulation.

Neither *Duselis* patent discloses an embodiment of bleached fibers in the claimed range. For all formulations containing bleached fibers, the only applicable embodiment comprises 11 weight percent bleached fibers per total dry formulation. (see Examples 2, 6, 7, and 8). The prior art embodiment of 11 weight percent *falls outside of* the upper limit (3.4%) of the claimed range of bleached fibers by more than **three-fold**. However, to anticipate, a prior art patent must include a specific embodiment *in the claimed range*. In *Atofina v. Great Lakes Chemical Corp.*, 78 USPQ2d 1417 (Fed. Cir. 2006), in reversing the lower court's finding of anticipation based on overlapping temperature ranges, the Federal Circuit held that a genus cannot anticipate a species claim even through the claimed temperature range (330 to 450 °C) overlapped the range taught by the prior art patent (100 to 500 °C), because no specific embodiment was disclosed in the prior art patent that taught the claimed range. *Id.* at 1423-24; see MPEP 2131.03. The *Duselis* patents fail to disclose an embodiment of bleached fibers in the claimed range and therefore do not anticipate.

**REJECTIONS UNDER 35 U.S.C. § 103**

Claims 1, 4-9, 11, 28, and 30-34 were rejected under 35 U.S.C. § 103(a) as being unpatentable over the *Duselis* patents each alone, or in view of Cook et al. (U.S. Patent No. 6,942,726) and Gregerson et al. (EP 263723). Reconsideration of the rejection under 35 U.S.C. § 103 is requested because the criticality of the claimed range of bleached fibers has been demonstrated which rebut the prima facie showing of obviousness over the *Duselis* patents. The *Gregerson* and *Cook* references do not overcome the deficiencies of the *Duselis* patents.

The claims recite ranges of bleached fibers that produce unexpected results. As shown in FIGS. 2, 3 and 4 of the pending application, unexpected results were achieved for improved modulus of rupture, strain, and toughness, respectively, in composite materials that contained between 12 and 17 weight percent bleached cellulose fibers per total cellulose fiber content. FIG. 2 shows that bleached cellulose fibers at 12 to 17 weight percent per fiber blend unexpectedly improves the modulus of rupture in the fiber-cement composites. Specifically, unexpected dose-dependent results are shown in the claimed range. FIG. 3 shows that bleached cellulose fibers at 12 to 17 weight percent is a critical range and unexpectedly increases strain resistance in fiber-cement composites. FIG. 4 shows that bleached cellulose fibers at 12 to 17 weight percent again is a critical range that provides unexpectedly increases toughness in fiber-cement composites. Comparable observations are not disclosed or suggested by the *Duselis* patents.

*Gregerson* teaches utilizing the bleached to unbleached fibers in a **3:1** ratio or **75%** of bleached fibers per total cellulose fibers. *Gregerson* fails to provide any suggestion of the unexpected results obtained with the claimed range of 10 to 17 weight percent bleached fibers per total cellulose fibers. Examples 7 and 8 of *Gregerson* are relevant. Example 7 of *Gregerson* discloses the use of 1250 kg EO (which *Gregerson* indicates is bleached cellulose) in combination with 400 kg Sandame K (which *Gregerson* indicates is unbleached cellulose), which corresponds to about **75%** [ $75\% = 1250\text{kg} / (1250\text{kg} + 400\text{kg})$ ] bleached fibers of total cellulose fibers. This far exceeds the claimed range. Next, Example 8 discloses the use of 9 parts bleached fibers (EO) and 3 parts unbleached fibers (Sandame K) for a total

cellulose fibers of 12 parts. The bleached fibers comprise 9 parts of 12 parts total cellulose fibers, or **75 %** which also significantly exceeds the claimed range.

*Gregerson* does not remedy the deficiencies of the *Duselis* patents. Further, *Cook* also does not remedy the deficiencies of the *Duselis* patents.

“Applicants can rebut a prima facie case of obviousness based on overlapping ranges by showing the criticality of the claimed range.” MPEP § 2144.05. Applicant submits that the criticality of the claimed range of 10 to 17 weight percent of bleached fibers per total fibers has been demonstrated. Reconsideration of the pending claims for allowance is respectfully requested.

Respectfully submitted,  
GARDERE WYNNE SEWELL LLP

/Scott C. Sample/

Scott C. Sample  
Registration No. 52,189  
(214) 999-4712  
October 6, 2010